Dapsone (oral)
| File:Dapsone.svg | |
| File:Dapsone3d.png | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 70 to 80% |
| Protein binding | 70 to 90% |
| Metabolism | Hepatic (mostly CYP2E1-mediated) |
| Elimination half-life | 20 to 30 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C12H12N2O2S |
| Molar mass | 248.302 gmol-1 |
|
WikiDoc Resources for Dapsone (oral) |
|
Articles |
|---|
|
Most recent articles on Dapsone (oral) Most cited articles on Dapsone (oral) |
|
Media |
|
Powerpoint slides on Dapsone (oral) |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Dapsone (oral) at Clinical Trials.gov Trial results on Dapsone (oral) Clinical Trials on Dapsone (oral) at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Dapsone (oral) NICE Guidance on Dapsone (oral)
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Dapsone (oral) Discussion groups on Dapsone (oral) Patient Handouts on Dapsone (oral) Directions to Hospitals Treating Dapsone (oral) Risk calculators and risk factors for Dapsone (oral)
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Dapsone (oral) |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Dapsone(diamino-diphenyl sulphone) is an pharmacological medication most commonly used in combination with rifampicin and clofazimine as multidrug therapy (MDT) for the treatment of Mycobacterium leprae infections (leprosy).
History
In the early 20th century the German chemist Paul Ehrlich was developing theories of selective toxicity based largely on the ability of certain dyes to kill microbes. Gerhard Domagk, who would later win a Nobel Prize for his efforts, made a major breakthrough in 1932 with the discovery of the antibacterial prontosil red. Further investigation into the active chemicals involved led to the discoveries both of dapsone and of the antibacterial sulfonamides.[2]
Mechanism of action
As an antibacterial, dapsone inhibits bacterial synthesis of dihydrofolic acid. Though structurally distinct from dapsone, the sulfonamide group of antibacterial drugs also work in this way.
When used for the treatment of skin conditions in which bacteria do not have a role, the mechanism or action of dapsone is less well understood.
Indications
As well as being used in leprosy dapsone can also be used to treat dermatitis herpetiformis and other skin conditions including lichen planus. It is also sometimes used to prevent Pneumocystis pneumonia(PCP) in patients with HIV and to treat idiopathic thrombocytopenic purpura. It is used prophylactically to prevent Pneumocystis pneumonia and toxoplasmosis in patients unable to tolerate trimethoprim with sulfamethoxazole.[1]
Administration
Dapsone is administered orally as a 100mg tablet or alternatively as 25mg tablets.
Adverse effects
Effects on the blood
The most prominent side effects of this drug are dose-related hemolysis (which may lead to hemolytic anemia) and methemoglobinemia.[2] Agranulocytosis occurs rarely when dapsone is used alone but more frequently in combination regimens for malaria prophylaxis.[3] Abnormalities in white blood cell formation, including aplastic anaemia, are rare but the cause of the majority of deaths due to dapsone therapy.[4][5][6]
Effects on the liver
Toxic hepatitis and cholestatic jaundice have been reported by the manufacturer. Jaundice may also occur as part of the dapsone reaction or dapsone syndrome (see below). Dapsone is also known to inhibit the Cytochrome P450 system.
Other adverse effects
Other adverse effects include nausea, headache, and rash, which are common, and insomnia, psychosis and peripheral neuropathy. Effects on the lung occur rarely and may be serious though are generally reversible.[7]
Dapsone reaction
Hypersensitivity reactions occur in some patients. This reaction may be more frequent in patients receiving multiple drug therapy.[8][9][10]
The reaction always involves a rash and may also include fever, jaundice, and eosinophilia.[11][12][13][14][15] These symptoms will generally occur within the first six weeks of therapy or not at all, and may be ameliorated by corticosteroid therapy.[1]
Specific considerations
Certain patients are at higher risks of adverse effects when using dapsone. Some specific issues which should be considered are:[1]
- Related to the blood (a full blood count should be obtained prior to initiating therapy):
- Related to the liver (obtain liver function tests before starting therapy):
- Liver impairment
- Related to allergy:
- Sulfonamide allergy is associated with dapsone allergy
References
- ↑ 1.0 1.1 1.2 Rossi S, ed. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
- ↑ Jopling WH. Side-effects of antileprosy drugs in common use. Lepr Rev 1983; 54: 261–70.
- ↑ Firkin FC, Mariani AF. Agranulocytosis due to dapsone. Med J Aust 1977; 2: 247–51.
- ↑ Foucauld J, et al. Dapsone and aplastic anemia. Ann Intern Med 1985; 102: 139.
- ↑ Meyerson MA, Cohen PR. Dapsone-induced aplastic anaemia in a woman with bullous systemic lupus erythematosus. Mayo Clin Proc 1994; 69: 1159–62.
- ↑ Björkman A, Phillips-Howard PA. Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bull WHO 1991; 69: 297–304.
- ↑ Jaffuel D, et al. Eosinophilic pneumonia induced by dapsone. BMJ 1998; 317: 181.
- ↑ Richardus JH, Smith TC. Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Lepr Rev 1989; 60: 267–73.
- ↑ Kumar RH, et al. Dapsone syndrome—a five year retrospective analysis. Indian J Lepr 1998; 70: 271–6.
- ↑ Rao PN, Lakshmi TSS. Increase in the incidence of dapsone hypersensitivity syndrome—an appraisal. Lepr Rev 2001; 72: 57–62.
- ↑ Joseph MS. Hypersensitivity reaction to dapsone. Lepr Rev 1985; 56: 315–20.
- ↑ Jamrozik K. Dapsone syndrome occurring in two brothers. Lepr Rev 1986; 57: 57–62.
- ↑ Hortaleza AR, et al. Dapsone syndrome in a Filipino man. Lepr Rev 1995; 66: 307–13.
- ↑ Tomecki KJ, Catalano CJ. Dapsone hypersensitivity: the sulfone syndrome revisited. Arch Dermatol 1981; 117: 38–9.
- ↑ Kromann NP, et al. The dapsone syndrome. Arch Dermatol 1982; 118: 531–2.
External links
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Sulfonamide antibiotics
- Leprosy